Press Room

Webinar - Analytical Quality by Design Road Map

Start
Wednesday, March 15, 2017 - 14:00
End
Wednesday, March 15, 2017 - 17:00
Location: online
Analytical Quality by Design QbD | Hovione

 

 
Speakers
António Ramos - Analytical Chemist
Lúcia Volta e Sousa - PhD Student / Analytical Chemist

There is a current trend in pharmaceutical industry on applying Analytical Quality by Design (AQbD) to method development as a part of analytical method lifecycle. Indeed, there is a considerable interest in enhancing method understanding in order to reduce failures, increase method robustness and reliability through its lifecycle. Reversed Phase-Liquid Chromatography (RP-LC) is the widest technology used in any pharmaceutical analysis so its performance should be widely studied during method development in order to ensure its robustness throughout the entire lifecycle. So, the application of an AQbD approach through a RP-LC method development represents an excellent opportunity to enhance method development activities while turn time into knowledge.

At Hovione, new analytical stepwise methodology based on QbD principles, already used at Hovione for process development, is being developed and has been applied to RP-LC methods development. This involves several steps: from objectives pre-definition; followed by the selection of an appropriate technology; passing through a method understanding process of how potential sources of variability may affect method performance, through structured and scientific-based tools (ex: DoE);  and ends up with a risk mitigation phase, where all sources of variability are reduced and controlled based on method understanding. So, in order for you to understand Hovione's point of view for AQbD application, I invite you to assist this exciting webinar where is presented some case studies in RP-LC, that highlights the application of this new methodology, as well as the newly defined of important AQbD concepts, such as Analytical Target Profile, Method Operable Design Region, Normal Operable Range and Analytical Control Strategy.

Key Learning Objectives:

  • Application of QbD principles to reverse-phase liquid chromatography methods
  • Development strategy to obtained increased reliability and robustness over method's lifecycle
  • Evaluating the relevant QbD elements and establishing their combined performance to reduce failures and costs over method lifecycle

Join Hovione's Webinar NOW!

Time Option 1 Time Option 2
register-now
2:00 pm (GMT)

10:00 am (EST)
4:00 pm (GMT)

9:00 am (PST)

12:00 pm (EST)

 

 

 

 

 

 

You might be also interested in:

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026